Exact(2)
The Tox21 collaboration began formally in 2008 with Phase I (Proof of Concept) consisting of qHTS studies conducted at the National Institutes of Health Chemical Genomics Center (NCGC) in 1,536-well format 1,536-well formatt studies conducted in support of the U.S. EnvironmentandProtection Agency's (EPA) ToxCast™ program.
During Tox21 Phase I (proof of principle), many biochemical and cell-based assays were successfully developed and miniaturized in a 1,536-well 1,536-wellat for screening against the initial Tox21 collection of aplateimately 3,000 compounds in a quantitative high throughput screening (qHTS) platformatShukla et al. 2010; Tice et al. 2013).
Similar(6)
Mutagenesis was performed using i-proof Taq polymerase (BioRad) according to the manufacturer's directions.
25 The first results with this biologic agent in patients with psoriasis came from a randomized Phase I proof-of-concept clinical trial involving 36 patients diagnosed as having chronic plaque-type psoriasis.
The weak user's data constraint is active and data arrival to the weak user occurs at time t i. Proof.
x i ?. Proof The topology of ( X, ∥ ⋅ ∥ ) is induced by the cone metric d ( x, y ) = ∥ x − y ∥ and the topology of ( X, ⦀ ⋅ ⦀ ) is induced by the metric ρ ( x, y ) = ⦀ x − y ⦀.
The following holds: if (W -1) ij ≠ 0, then there exists some directed path j → i. Proof.
Lemma 3.2 F 1 ∘ F 2 ∈ USIC + ( I ) (resp. USIC − ( I ) ) for F 1, F 2 ∈ USIC + ( I ) (resp. USIC − ( I ) ). Proof By Lemma 2.2 in [29], we only need to prove that F 1 ∘ F 2 is R + -convex on I (resp. R − -convex on I).
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com